皮肤狼疮和皮肤狼疮红斑疾病面积和严重程度指数工具。
Cutaneous lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index instrument.
机构信息
Philadelphia VA Medical Center, Philadelphia, PA, USA.
出版信息
Rheum Dis Clin North Am. 2010 Feb;36(1):33-51, vii. doi: 10.1016/j.rdc.2009.12.001.
Abstract
This article provides an overview of cutaneous lupus erythematosus, including classification schemes, disease subtypes, and therapy. It also describes the Cutaneous Lupus Erythematosus Disease Area and Severity Index, a novel clinical outcome instrument that quantifies cutaneous activity and damage in cutaneous lupus erythematosus.
摘要
本文概述了红斑狼疮，包括分类方案、疾病亚型和治疗方法。它还描述了红斑狼疮疾病面积和严重程度指数，这是一种新型的临床结果评估工具，可量化红斑狼疮的皮肤活动和损伤。
相似文献
1
Cutaneous lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index instrument.
Rheum Dis Clin North Am. 2010 Feb;36(1):33-51, vii. doi: 10.1016/j.rdc.2009.12.001.
2
Pyoderma gangrenosum in a patient with bullous systemic lupus erythematosus.
Eur J Dermatol. 2002 Sep-Oct;12(5):485-7.
3
Clinical image: bullous lupus erythematosus.
Rheumatology (Oxford). 2018 Sep 1;57(9):1601. doi: 10.1093/rheumatology/key084.
4
Widespread vesiculobullous eruption in a 16-year-old male.
Acta Dermatovenerol Alp Pannonica Adriat. 2010 Oct;19(3):19-22.
5
The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus.
J Invest Dermatol. 2005 Nov;125(5):889-94. doi: 10.1111/j.0022-202X.2005.23889.x.
6
Bullous systemic lupus erythematosus: response to dapsone in two patients.
Indian J Dermatol Venereol Leprol. 2005 Jan-Feb;71(1):54-6. doi: 10.4103/0378-6323.13795.
7
Vesiculobullous rash in a patient with systemic lupus erythematosus.
Ann Allergy. 1993 Mar;70(3):196-203.
8
Cutaneous lupus erythematosus: factors related to cutaneous activity and damage in a cohort of 260 patients from A Coruña, Spain.
Lupus. 2020 Aug;29(9):1021-1030. doi: 10.1177/0961203320930094. Epub 2020 Jun 15.
9
Worsening skin damage in patients with cutaneous lupus erythematosus may predict development of systemic lupus erythematosus.
J Am Acad Dermatol. 2021 Feb;84(2):538-540. doi: 10.1016/j.jaad.2020.05.020. Epub 2020 May 11.
10
A 12-year retrospective review of bullous systemic lupus erythematosus in cutaneous and systemic lupus erythematosus patients.
Lupus. 2017 Oct;26(12):1278-1284. doi: 10.1177/0961203317699714. Epub 2017 Mar 30.
引用本文的文献
1
Topical Mupirocin Treatment Reduces Interferon and Myeloid Signatures in Cutaneous Lupus Erythematous Lesions Through Targeting of Staphylococcus Species.
Arthritis Rheumatol. 2025 Jun;77(6):705-715. doi: 10.1002/art.43079. Epub 2025 Jan 23.
2
Assessment of cutaneous disease activity in early lupus and its correlation with quality of life: a cross-sectional study.
Rheumatol Int. 2023 Oct;43(10):1835-1840. doi: 10.1007/s00296-023-05353-y. Epub 2023 Jun 13.
3
Molecular Characterization of Hepatitis B Virus Infection in a Patient with Cutaneous Lupus Erythematosus.
Diagnostics (Basel). 2022 Nov 19;12(11):2866. doi: 10.3390/diagnostics12112866.
4
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Arthritis Rheumatol. 2023 Feb;75(2):242-252. doi: 10.1002/art.42391. Epub 2022 Nov 11.
5
Diagnosis and Management of Cutaneous Manifestations of Autoimmune Connective Tissue Diseases.
Clin Cosmet Investig Dermatol. 2022 Oct 26;15:2285-2312. doi: 10.2147/CCID.S360801. eCollection 2022.
6
Nonlesional lupus skin contributes to inflammatory education of myeloid cells and primes for cutaneous inflammation.
Sci Transl Med. 2022 Apr 27;14(642):eabn2263. doi: 10.1126/scitranslmed.abn2263.
7
Update on Epidemiology and Clinical Assessment Tools of Cutaneous Lupus Erythematosus and Dermatomyositis.
Curr Dermatol Rep. 2013 Mar;2(1):48-57. doi: 10.1007/s13671-012-0037-3. Epub 2013 Jan 24.
8
Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Rheumatol Ther. 2020 Dec;7(4):893-908. doi: 10.1007/s40744-020-00236-1. Epub 2020 Sep 29.
9
Robust measurement of clinical improvement in patients with cutaneous lupus erythematosus.
Lupus Sci Med. 2020 Jan 27;7(1):e000364. doi: 10.1136/lupus-2019-000364. eCollection 2020.
10
Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus.
JAMA Dermatol. 2018 Dec 1;154(12):1432-1440. doi: 10.1001/jamadermatol.2018.3793.
本文引用的文献
1
Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.
Lupus. 2009 Jul;18(8):735-9. doi: 10.1177/0961203308101714.
2
Lupus erythematosus masquerading as erythema multiforme: does Rowell syndrome really exist?
Dermatol Online J. 2009 Feb 15;15(2):5.
3
Efficacy and safety of pulsed dye laser treatment for cutaneous discoid lupus erythematosus.
J Am Acad Dermatol. 2009 Apr;60(4):626-32. doi: 10.1016/j.jaad.2008.11.904.
4
Clinically relevant information about cutaneous lupus erythematosus.
Arch Dermatol. 2009 Mar;145(3):316-9. doi: 10.1001/archdermatol.2008.582.
5
Lenalidomide for the treatment of resistant discoid lupus erythematosus.
Arch Dermatol. 2009 Mar;145(3):303-6. doi: 10.1001/archdermatol.2009.30.
6
Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking.
Arch Dermatol. 2009 Mar;145(3):244-8. doi: 10.1001/archdermatol.2008.592.
7
The 100th anniversary of lupus erythematosus tumidus.
Autoimmun Rev. 2009 May;8(6):441-8. doi: 10.1016/j.autrev.2008.12.010. Epub 2009 Jan 20.
8
Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation.
Arch Dermatol Res. 2009 Jan;301(1):65-70. doi: 10.1007/s00403-008-0890-x. Epub 2008 Sep 17.
9
Drug-induced lupus erythematosus.
Arch Dermatol Res. 2009 Jan;301(1):99-105. doi: 10.1007/s00403-008-0895-5. Epub 2008 Sep 17.
10
Lupus erythematosus panniculitis.
Dermatol Clin. 2008 Oct;26(4):453-63, vi. doi: 10.1016/j.det.2008.06.002.
Zotero 插件